common
marmoset
new
world
primat
belong
callitrichida
famili
weigh
marmoset
shown
outstand
model
studi
age
reproduct
neurosci
toxicolog
infecti
diseas
regard
suscept
infecti
agent
exquisit
nhp
model
viral
protozoan
bacteri
agent
well
prion
marmoset
provid
advantag
small
anim
model
high
contain
coupl
immunolog
repertoir
nonhuman
primat
suscept
wild
type
nonadapt
virus
common
marmoset
new
world
primat
belong
callitrichida
famili
anim
nativ
atlant
coastal
forest
northeastern
brazil
suppli
research
come
nation
primat
research
center
pharmaceut
compani
breed
facil
small
size
adult
weigh
gram
lifespan
marmoset
rel
compact
compar
nonhuman
primat
nhp
anim
reach
matur
month
age
produc
offspr
three
year
age
reach
old
age
year
age
compress
lifespan
marmoset
attract
scientif
research
number
marmoset
avail
research
scale
quickli
need
aris
natur
reduc
larg
number
anim
need
marmoset
shown
outstand
model
studi
age
reproduct
neurosci
toxicolog
infecti
diseas
regard
suscept
infecti
agent
exquisit
nhp
model
viral
protozoan
bacteri
agent
well
prion
carri
herp
b
viru
macacin
herpesviru
unlik
macaqu
harbor
viru
especi
desir
trait
handl
monkey
purpos
review
focu
use
marmoset
high
biocontain
highlight
reflect
human
diseas
hemorrhag
fever
oftenfat
diseas
caus
rna
virus
belong
primarili
bunyavirida
arenavirida
filovirida
famili
high
morbid
induc
lack
approv
vaccin
therapi
mani
virus
handl
safe
use
biosafeti
level
practic
diseas
sever
import
case
diseas
patient
travel
endem
area
potenti
use
agent
biolog
weapon
underscor
need
understand
viral
pathogenesi
well
develop
intervent
strategi
uniqu
characterist
marmoset
make
especi
suit
high
biocontain
research
particular
small
size
anim
oppos
larger
nhp
speci
make
husbandri
less
cumbersom
timeconsum
thu
use
monkey
high
contain
safer
less
expens
use
larger
nhp
counterpart
addit
current
small
anim
model
hemorrhag
fever
diseas
requir
use
rodentadapt
virus
shown
especi
predict
efficaci
nhp
marmoset
advantag
suscept
infect
wildtyp
virus
desir
test
vaccin
therapeut
lassa
viru
member
arenavirida
famili
caus
agent
lassa
fever
fatal
diseas
affect
peopl
year
western
africa
overal
instanc
fatal
viru
transmit
natur
rodent
reservoir
human
via
contamin
rodent
excreta
close
contact
infect
individu
follow
incub
period
day
diseas
mark
gradual
onset
symptom
includ
fever
weak
malais
diseas
progress
nausea
vomit
diarrhea
abdomin
pain
often
observ
hemorrhag
mucos
surfac
conjunctiv
hemorrhag
gastrointestin
vagin
bleed
occur
less
case
late
stage
diseas
mark
shock
seizur
coma
culmin
death
demonstr
singl
subcutan
inocul
common
marmoset
lassa
viru
result
system
viral
diseas
fatal
outcom
histolog
featur
similar
describ
fatal
diseas
human
experiment
infect
result
system
viral
diseas
high
viremia
elev
liver
enzym
decreas
level
albumin
plasma
weight
loss
sever
morbid
day
inocul
histolog
analysi
tissu
infect
anim
identifi
lesion
compar
describ
human
case
fatal
lassa
fever
includ
hepat
adren
necrosi
lymphoid
deplet
interstiti
nephriti
model
also
demonstr
viru
induc
alter
target
tissu
would
expect
impair
adapt
immun
respons
consist
observ
immunosuppress
contribut
lassa
diseas
progress
human
fatal
lassa
fever
case
lassa
virusinfect
experiment
anim
liver
one
affect
organ
particip
system
breakdown
promin
morpholog
featur
lassa
virusinduc
hepat
common
marmoset
multifoc
hepat
necrosi
mild
inflamm
present
predominantli
macrophag
ii
near
absenc
lymphocyt
necrot
foci
iv
complet
lack
express
mhcii
antigen
v
hepatocyt
prolifer
judg
posit
stain
find
suggest
evas
normal
immun
respons
virul
factor
develop
lassa
virusinduc
hepat
lymphoid
deplet
major
find
human
also
observ
spleen
lymph
node
lassa
virusinfect
marmoset
chang
pronounc
lymph
node
mark
loss
follicl
infiltr
larg
number
histiocyt
addit
liver
tissu
mark
reduct
intens
hladr
stain
also
observ
lymph
node
lassa
virusinfect
marmoset
alter
spleen
includ
reduct
overal
number
lymphocyt
lassainfect
marmoset
immunosuppress
phenotyp
lassa
viru
infect
previous
base
detect
proinflammatori
cytokin
immunomodulatori
molecul
cultur
medium
human
cell
infect
vitro
plasma
experiment
infect
anim
lassa
fever
patient
junin
viru
caus
agent
argentin
hemorrhag
fever
licens
vaccin
specif
antivir
exist
unit
state
human
becom
infect
inhal
aerosol
rodent
excrement
blood
direct
contact
infect
anim
mortal
rate
diseas
earli
clinic
symptom
infect
includ
fever
fatigu
nausea
mild
hemorrhag
petechia
usual
skin
mucos
tissu
initi
target
macrophag
recruit
addit
sentinel
cell
secret
cytokin
chemokin
lead
dissemin
viral
infect
dissemin
infect
lead
lack
immun
control
increas
endotheli
leakag
platelet
defect
common
marmoset
success
use
pathogenesi
protect
studi
junin
viru
infect
callithrix
jacchu
prototyp
strain
junin
viru
produc
fatal
diseas
multifoc
hemorrhag
characterist
microscop
lesion
meningoenceph
lymphocyt
deplet
lymphat
tissu
hepatocyt
necrosi
interstiti
pneumonia
variabl
decreas
bone
marrow
cellular
high
viru
concentr
correl
lesion
presenc
viru
antigen
famili
filovirida
predominantli
consist
two
genera
ebolaviru
ebov
marburgviru
marv
genera
ebov
compris
five
speci
prototyp
zair
sudan
bundibugyo
forest
viru
formerli
known
ivori
coast
reston
ebov
zair
sudan
bundibugyo
well
marv
respons
sporad
highli
lethal
outbreak
sever
hemorrhag
fever
human
ape
subsaharan
africa
mortal
rate
sometim
approach
although
primari
anim
host
filovirus
still
somewhat
unclear
tropic
viral
diseas
bat
strongli
implic
possibl
reservoir
howev
descript
ebov
reston
pig
asia
serv
warn
potenti
eas
virus
may
aris
spread
divers
speci
popul
fdaapprov
vaccin
specif
treatment
current
avail
filovirus
although
recent
advanc
vaccin
develop
promis
common
marmoset
suscept
experiment
infect
virus
famili
filovirida
intramuscular
inocul
littl
pfu
either
ebov
marv
induc
patholog
featur
similar
observ
human
diseas
notabl
anim
experienc
thrombocytopenia
neutrophilia
dissemin
intravascular
coagul
marmoset
high
viru
load
blood
tissu
regardless
dose
viru
agent
furthermor
small
nhp
experienc
diseas
syndrom
compar
report
nhp
model
current
use
studi
filoviru
diseas
inocul
marmoset
zair
ebolaviru
result
acut
diseas
marmoset
experienc
anorexia
coincid
onset
fever
shortli
initi
find
anorexia
vari
degre
recumb
observ
culmin
prostrat
death
day
postchalleng
previou
work
shown
intramuscular
inocul
macaqu
marv
result
similar
cours
diseas
howev
overal
diseas
progress
delay
experiment
inocul
marmoset
marv
also
result
delay
onset
diseas
death
occur
day
later
seen
marmoset
infect
ebov
howev
cours
marburg
diseas
marmoset
rapid
seen
macaqu
death
occur
sever
day
sooner
macaqu
marmoset
infect
either
filovirus
display
neutrophilia
lymphopenia
thrombocytopenia
hematolog
abnorm
also
seen
human
infect
shortli
infect
overal
platelet
count
decreas
neutrophil
number
increas
concomit
decreas
lymphocyt
number
addit
infect
marmoset
show
biochem
sign
liver
involv
earli
infect
elev
marker
liver
function
alt
alp
ggt
gross
examin
liver
reveal
hepatomegali
pale
foci
throughout
lobe
microscop
examin
section
liver
reveal
necrosi
mild
moder
inflamm
similar
find
document
macaqu
model
filoviru
infect
fatal
human
case
fatal
human
case
character
hemorrhag
bleed
site
venipunctur
coagul
abnorm
coagulopathi
observ
human
time
exist
absenc
rash
patient
infect
ebov
develop
maculopapular
rash
marmoset
develop
petechi
rash
infect
either
marv
ebov
respect
appear
similar
african
green
monkey
model
filoviru
infect
evid
marmoset
mimic
human
diseas
microscop
examin
tissu
ebovinfect
anim
show
widespread
fibrin
deposit
hallmark
coagul
abnorm
ebov
infect
marmoset
caus
sever
dissemin
viral
infect
character
princip
microthrombosi
multipl
organ
dissemin
intravasculatur
coagul
marvinfect
anim
display
moder
fibrin
deposit
spleen
find
similar
seen
human
infect
macaqu
interestingli
sign
coagulopathi
characterist
primat
infect
observ
variabl
rodent
model
eastern
equin
enceph
eee
arthropod
born
viral
enceph
endem
north
america
along
unit
state
atlant
coast
affect
human
equin
sever
case
human
infect
begin
fever
chill
headach
vomit
rapidli
progress
disorient
seizur
coma
due
enceph
eeev
caus
greater
mortal
specif
treatment
alphavirus
highli
infecti
aerosol
rout
develop
countermeasur
high
prioriti
intranas
exposur
north
american
strain
eeev
caus
lethal
enceph
marmoset
decreas
leukocyt
observ
na
eeevinfect
marmoset
within
hr
infect
follow
mark
leukocytosi
prior
death
euthanasia
similar
human
case
leukocytosi
marmoset
compos
mixtur
lymphocyt
granulocyt
patholog
lesion
cn
na
eeevinfect
marmoset
similar
describ
human
case
eeev
caus
neuron
loss
neuronophagia
perivascular
cuff
focal
diffus
accumul
inflammatori
cell
leptomening
cn
vascular
lesion
breakdown
structur
vessel
wall
appear
thrombi
extravas
red
blood
cell
often
note
foci
necrosi
grey
white
matter
also
report
sever
eee
case
diseas
area
cn
frequent
subject
sever
lesion
includ
cerebr
cortex
basal
ganglia
thalamu
hippocampu
brainstem
contrast
lesion
cerebellum
spinal
cord
common
find
human
eee
south
american
eeev
strain
attenu
infect
marmoset
find
consist
data
deriv
mous
studi
two
report
fatal
human
enceph
case
eee
south
america
human
like
expos
south
america
develop
appar
infect
eeev
poor
infect
andor
virul
south
american
strain
sever
acut
respiratori
syndrom
sar
emerg
infect
peopl
caus
death
case
human
infect
primarili
present
pneumon
may
also
develop
hepat
gastrointestin
renal
patholog
older
peopl
often
associ
increas
sar
pathogen
death
result
acut
respiratori
distress
syndrom
intratrach
inocul
marmoset
cell
cultur
supernat
contain
sarscov
develop
diseas
featur
similar
human
diseas
mononuclear
cell
interstiti
pneumon
accompani
multinucl
syncyti
cell
edema
bronchiol
observ
sarsinfect
anim
alveolar
macrophag
pneumocyt
appear
site
viral
antigen
local
furthermor
pulmonari
tissu
extract
obtain
necropsi
well
tracheobronchi
lymph
node
myocardium
detect
level
viral
rna
hepat
inflamm
observ
anim
predominantli
multifoc
lymphocyt
hepat
accompani
necrosi
individu
hepatocyt
find
provid
evid
marmoset
relev
nhp
studi
sarscov
pathogenesi
marmoset
emerg
viabl
nhp
model
studi
high
biocontain
infecti
diseas
agent
tabl
advantag
use
marmoset
mimic
human
diseas
small
size
provid
cost
save
larger
nhp
speci
requir
husbandri
techniqu
less
time
consum
fewer
biosafeti
consider
known
carri
endogen
viru
harm
human
marmoset
nhp
provid
distinct
advantag
rodent
speci
includ
immunolog
repertoir
close
resembl
human
test
vaccin
therapi
high
consequ
pathogen
advanc
robust
anim
model
valid
countermeasur
requir
sporad
natur
mani
high
consequ
pathogen
incid
agent
predict
therefor
phase
iii
efficaci
trial
feasibl
us
food
drug
administr
fda
declar
new
regul
altern
licens
pathway
pharmaceut
product
target
highli
lethal
pathogen
evalu
field
possibl
anim
rule
allow
approv
provid
satisfactori
efficaci
data
gener
two
anim
model
case
viral
hemorrhag
fever
marmoset
offer
advantag
rodent
speci
altern
small
anim
model
regard
filoviru
research
addit
need
rodent
adapt
viru
mous
guinea
pig
filoviru
model
good
predictor
efficaci
higher
speci
marmoset
model
provid
advantag
small
anim
model
high
contain
coupl
immunolog
repertoir
nhp
suscept
wild
type
nonadapt
virus
undoubtedli
increas
use
marmoset
model
acceler
preclin
develop
vaccin
therapeut
high
consequ
pathogen
common
marmoset
new
world
primat
weigh
marmoset
exquisit
nhp
model
viral
protozoan
bacteri
agent
well
prion
marmoset
emerg
viabl
model
studi
high
biocontain
pathogen
model
describ
ebola
marburg
lassa
sarscoa
eee
virus
use
marmoset
acceler
develop
countermeasur
high
consequ
pathogen
